https://doi.org/10.4081/reumatismo.2024.1658
Systemic lupus erythematosus induced by anti-tumor necrosis factor α therapy in inflammatory rheumatic diseases: a case series
Accepted: 3 May 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
This case series aims to characterize the development of systemic lupus erythematosus (SLE) induced by anti-tumor necrosis factor α (anti-TNFα) therapy in patients with inflammatory rheumatic diseases, namely rheumatoid arthritis (RA), spondylarthritis (SpA), and psoriatic arthritis (PsA). Patients with a diagnosis of SLE induced by anti-TNFα therapy and registered on the Rheumatic Diseases Portuguese Register (Reuma.pt) who started their first anti-TNFα between 2001 and 2020 were included. Demographic, clinical, and laboratory data were obtained by consulting Reuma.pt. The diagnosis of SLE induced by anti-TNFα was considered if there was a temporal relationship between the onset of anti-TNFα therapy and manifestations (clinical and immunological) in accordance with the American College of Rheumatology/European League Against Rheumatism criteria (2019). A total of 607 patients with inflammatory rheumatic diseases and six cases of SLE induced by anti-TNF-α therapy were reviewed: two patients were affected by RA, three patients by SpA, and one by PsA. All these patients had articular and constitutional symptoms that improved after discontinuation of the anti-TNFα agent. After switching to a second anti-TNFα agent, there was no recurrence of SLE over time. The development of SLE secondary to anti-TNFα agents in inflammatory rheumatic patients is rare. In this case series, all patients had a mild disease that improved after therapy discontinuation without recurrence of the disease. SLE induced by anti-TNFα should be considered in the follow-up of RA, SpA, and PsA patients.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- D.G. Fernández Ávila, M. Rivera Maldonado, L.P. Charry Anzola, Epidemiology and demographics of cutaneous lupus erythematosus in Colombia between 2015 and 2019 , Reumatismo: Vol. 75 No. 1 (2023)
- M. Radin, G. El Hasbani, A. Barinotti, D. Roccatello, I. Uthman, A. Taher, S. Sciascia, Quality of life measures in systemic lupus erythematosus: a systematic review , Reumatismo: Vol. 73 No. 4 (2021)
- P. Fadda, L. La Civita, A.L. Zignego, C. Ferri, A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome , Reumatismo: Vol. 54 No. 4 (2002)
- S. Stisi, P. Sarzi-Puttini, M. Benucci, G. Biasi, S. Bellissimo, R. Talotta, F. Atzeni, RETRACTED - Pain in systemic sclerosis , Reumatismo: Vol. 66 No. 1 (2014)
- F. Atzeni, P. Sarzi-Puttini, Early rheumatoid arthritis , Reumatismo: Vol. 59 No. 2 (2007)
- M. Vadacca, D. Margiotta, D. Sambataro, F. Buzzulini, M. Lo Vullo, A. Rigon, A. Afeltra, BAFF/APRIL pathway in Sjögren syndrome and systemic lupus erythematosus: relationship with chronic inflammation and disease activity , Reumatismo: Vol. 62 No. 4 (2010)
- M. Marrone, A. Chialà, M. Tampoia, F. Iannone, L. Raho, M. Covelli, V. Grattagliano, N. Pansini, G. Lapadula, Prevalence of anti-CCP antibodies in systemic sclerosis , Reumatismo: Vol. 59 No. 1 (2007)
- L. Quartuccio, S. Salvin, M. Saracco, S. Lombardi, M. Fabris, E. Mansutti, M. Maset, S. Pellerito, S. De Vita, Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFα agents failed are associated with response to rituximab in rheumatoid arthritis , Reumatismo: Vol. 61 No. 3 (2009)
- M. Benucci, A. Damiani, F. Li Gobbi, V. Grossi, M. Infantino, A. Arena, M. Manfredi, Jaccoud’s arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment , Reumatismo: Vol. 69 No. 2 (2017)
- M. Bellan, S. Bor, A. Gibbin, A. Gualerzi, S. Favretto, G. Guaschino, R. Bonometti, A. Rossini, D. Sola, R. Pedrazzoli, G.P. Carnevale Schianca, M. Pirisi, P.P. Sainaghi, Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis , Reumatismo: Vol. 70 No. 4 (2018)
<< < 8 9 10 11 12 13 14 15 16 17 > >>
You may also start an advanced similarity search for this article.
